The importance of oxidative stress has been indicated by increased plasma and arterial lipid peroxide and altered antioxidant status in atherosclerotic patients [1]. The uptake of oxidized LDL (oxLDL) by monocytes located in the arteries may lead to their transformation into macrophages, residential macrophages and finally foam cells [2]. OxLDL interacts with β-2-glycoprotein-I (β2GPI), forming circulating oxLDL/β2GPI complexes that are etiologically important in the formation of foam cells, an early stage of atherosclerosis. Recent studies have shown that the measurement of oxLDL/β2GPI complexes in patients with cardiovascular diseases provides a novel marker for those patients prone to or at risk for coronary heart disease [3].

Numerous observational studies indicate that postmenopausal hormone replacement therapy (HRT) is associated with lower risk for coronary heart disease [4, 5]. Several hypotheses regarding the atheroprotective effect of HRT have been proposed. Some studies have linked the development of protective effects to an improved antioxidant status [6, 7]. The mechanism responsible for HRT-associated oxidative stress is not fully elucidated. Estrogen has been reported to have potent antioxidant properties, which may exert their influence through reducing oxidized lipids [8].
In this study, the effects of HRT on serum levels of oxLDL/β2GPI complexes were investigated in non-obese normolipidemic postmenopausal subjects. We also measured the total serum antioxidant capacity (TAC) as ferric reducing ability of plasma (FRAP) and related these to HRT and oxLDL/β2GPI complexes level. We hypothesized that HRT would relate positively with antioxidant status.

**Materials and Methods**

**Subjects**

Sixty nonobese normolipidemic postmenopausal women (54.7±4.6 years of age, BMI 25.2 ±1.6 kg/m²) were selected through personal contacts of more than 400 volunteers who were admitted to two clinical centers at the Isfahan University of Medical Sciences. The mean age at menopause in the population was 46.5±3.7 years. Details of the study design and sampling have been reported earlier [9]. Briefly, Women were considered postmenopausal if they had no menstrual periods for at least 12 months and serum follicle-stimulating hormone (FSH) of >35 IU/L without other obvious pathological or physiological cause. Exclusion criteria were age ≥65 years, BMI ≥30 kg/m², a previous hospital admission related to cardiovascular disease, and a previous diagnosis of angina, hypercholesterolemia, or diabetes. In addition, none of them had smoking habits or had taken medications or vitamin supplements in the 4 months before the study. During the study period the subjects maintained their regular physical lifestyle and activity. The subjects were asked to record any consumption of drugs not included in the experimental design.

Study participants were assigned to a 90-day experimental period. During the experimental period all subjects received oral HRT with estrogen plus progestagen (0.625mg of conjugated equine estrogen plus 2.5mg of medroxyprogesterone acetate per day; Iran Hormone Co., Iran). The study protocol was approved by the institutional review board and the ethic committee of Isfahan University of Medical Sciences, and all patients gave written informed consent. Evaluation of treatment compliance was ascertained by weekly interview as well as by pill count.

**Blood sampling and analysis**

Fasting blood samples were taken at the beginning of the study and at the end of hormone therapy. Serum aliquots were obtained by centrifugation. Samples were deep frozen for later analysis. Serum total cholesterol, triglyceride (TG), HDL-C and LDL-C were determined by using standard enzymatic procedures [10] on a BT 3000 autoanalyzer (Biotecnica Institute, IT). TAC was determined by FRAP method, which is based on the reduction of a colorless ferric tripyridyltriazine complex to a blue ferrous complex by the antioxidants in the plasma. The change in absorbance at 593nm is directly related to the total reducing power of electron donating antioxidants present in the plasma [11]. The serum oxLDL/β2GPI complexes concentration was determined using ELISA (Cayman Chemical, Ann Arbor, MI). The overall coefficients of variation for these assays were between 1.9 and 5.2%. All analyses were run in a blinded fashion.

**Data analyses**

Variables were analysed for distribution and a logarithmic transformation was applied to the values of TG/HDL-C ratio to normalize distribution of the data. P-value <0.05 was considered statistically significant. All analyses were carried out using SPSS for windows version 11.0 (SPSS Inc., Chicago, IL).

**Results**

Compliance to the experimental intervention was good according to data records. The HRT led to a significant reduction in LDL-C (P=0.02) as compared with the baseline (Table 1). Hormone therapy was associated with significantly higher concentrations of HDL-C (P=0.001). Also, beneficial modifications expressed as a non-significant decrease in the log TG/HDL-C ratio (P=0.061) were observed at the third month of treatment with respect to basal values.

Fig. 1 show parameters related to the oxidant-antioxidant status before hormone therapy and after 90 days of therapy. Analysis of TAC by FRAP method found a significantly higher antioxidant capacity (15%, P=0.024) mean value at the third month than at the baseline. However, there was no statistically significant change in the oxLDL/β2GPI complexes level (3%, P=0.30) in response to HRT. The ratio of oxLDL/β2GPI to HDL-C which expresses lipoprotein oxidative status [12], were calculated in each case. The oxLDL/β2GPI to HDL-C ratio was significantly lower in samples obtained after HRT (P= 0.018, Fig. 1). Our data showed no significant correlation between TAC and oxLDL/β2GPI complexes changes related to HRT.
HRT effect on oxLDL/β2GPI

1031

OxLDL/β2GPI complexes level was correlated with total cholesterol ($r=0.31$, $P=0.01$) and LDL-C ($r=0.28$, $P=0.03$) both before and after HRT. No similar association was observed for TAC and other lipid parameters.

**Discussion**

Postmenopausal hormone therapy has been generally recognized as a component of preventive health care for elderly women, with many benefits including improvement in climacteric symptoms and prevention of osteoporosis and cardiovascular disease [13, 14]. Controversies still exist regarding the beneficial protecting effects of HRT. Several clinical trials demonstrated that HRT may increase the risk of cardiovascular complication. The results of these clinical trials are in contrast to those of observational studies which suggested a protective role of hormone therapy [4]. Postmenopausal hormone therapy may exert its anti-atherogenic effect through their antioxidant properties, preventing oxidative modification of LDL, as well as foam-cell formation and atherogenesis [15]. Recently, interest has focused on novel plasmatic biomarkers of lipid peroxidation such as levels of oxLDL/β2GPI complexes. For the first time, we examined whether conventional HRT supplementation in postmenopausal women could affect their oxLDL/β2GPI complexes.

Adherence to the HRT was supported by the quality of the treatment records. The effects on serum lipid composition found after the HRT agree with previous studies [16] and has been discussed earlier by us [9].

Total antioxidative capacity of serum is related to nonenzymatic and enzymatic systems. TAC measurement is considered to be the most appropriate way to assess the performance of the entire antioxidant system. The effects of short- and long-term HRT on plasma antioxidant status has been demonstrated in a wide variety of studies. Hernandez et al. [17] have shown that estrogen intake is associated with an increase in plasma levels of anti-oxidants of ovariectomized rats. In accor-

---

**Table 1** Effects of hormone replacement therapy (HRT) on serum lipid and lipoprotein levels

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>HRT, 3rd month</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>202±41</td>
<td>200±35</td>
<td>0.52</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>148±51</td>
<td>150±53</td>
<td>0.59</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>45±11</td>
<td>50±11</td>
<td>0.001</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL)</td>
<td>124±27</td>
<td>116±25</td>
<td>0.02</td>
</tr>
<tr>
<td>log Triglyceride/HDL cholesterol</td>
<td>0.51±0.19</td>
<td>0.46±0.18</td>
<td>0.061</td>
</tr>
</tbody>
</table>

1 Values are expressed as means±SD, $P<0.05$ (paired $t$-test).

---

**Fig. 1** Effects of hormone replacement therapy (HRT) on oxLDL/β2GPI (a), total antioxidant capacity (TAC) (b), oxLDL/β2GPI to HDL-C ratio (c) in the studied subjects. Values are means ± SE. $P < 0.05$ (paired sample $t$-test).
dance, determination of the TAC by FRAP assay in our study showed a significant increase in antioxidant status of plasma by HRT. The 3-month exposure time was considered long enough because comparable clinical studies with hormone therapy demonstrate significant changes in serum lipids and antioxidative enzyme activity [18, 19] or even during the menstrual cycle [20].

It has been reported that estradiol combined with intrauterine levonorgestrel decreased LDL oxidation in vivo [21]. Accordingly, lower lipid peroxidation were found in postmenopausal women with both the estrogen alone and combined with progestin oral HRT when compared to the control group [22], suggesting that HRT is beneficial in the protection against oxidative stress. In our study we observed that hormone therapy in postmenopausal groups caused an increase in TAC and an increase in HDL, but we did not observe a change in oxLDL/β2GPI complexes. There may be a complex interaction between different progestins and routes of HRT administration on metabolic and oxidative markers [22-24]. Therefore, the magnitude and type of effect according to the progesterone content and route of administration may vary between studies. In line with our study, it has been shown that the lipoprotein susceptibility to oxidation, assessed by ex vivo analyses, was not affected by oral combined HRT with estradiol and dydrogesteron [25]. Controversially, it has been shown that oral conjugated equine estrogen induced increase in plasma TG concentration can reduce the size of LDL particles, which are more susceptible to oxidation [24]. Therefore, a possible increase in susceptibility of LDL to oxidation during HRT in the present study may be an explanation for there being no change in oxLDL/β2GPI complexes despite a significant improvement in serum antioxidant potential. OxLDL, not native LDL, binds β2GPI forming stable complexes. It has been suggested that oxLDL/β2GPI complexes are formed in the arterial wall where they are either internalized by macrophages to form foam cells and/or released back into the circulation [26]. It is possible that the interaction between β2GPI and oxLDL reduces the inflammatory properties of oxLDL while promoting its clearance from circulation [27]. HRT may influence the formation and clearance of oxLDL/β2GPI complexes partly through non-antioxidative processes by changing β2GPI expression level and/or macrophage scavenging activity. In support of this hypothesis, it has been shown that β2GPI is down regulated during inflammation [28]. Stable oxLDL/β2GPI complexes exert an indirect but significant role in atherosclerosis, which is still being elucidated. We found that oxLDL/β2GPI complexes correlated with total cholesterol and LDL-C, possibly reflecting the known positive correlation of cholesterol with atherosclerosis. Future studies examining multiple oxidative stress markers simultaneously will be required to attain a better understanding of the potential role of HRT in oxidative stress.

Because oxidative stress results primarily from an imbalance between oxidant and antioxidants, a combination of markers reflecting these two components appears to be clinically useful. The antioxidant properties of HDL have been well studied and the ratio of oxLDL/β2GPI complexes to HDL-C probably reflects better oxidative stress. Earlier reports suggest that, this ratio imbalance could be a useful marker for atherosclerosis in diabetic patients [12, 29]. In the current study, we have found a significant decrease in the oxLDL/β2GPI complexes to HDL-C ratio after HRT. These findings further support the findings of a less oxidative stress by the setting of HRT described here. The role of HRT as antioxidant is still not satisfactorily resolved [30]. The effect of combined estrogen/progestin therapy, which is now the preferred treatment for women with an intact uterus, has been investigated in our study. Future studies may focus on the impact of age and the differential effects of estrogen/progestin and estrogen only therapy.

Our findings showed that 3 months of HRT increased the plasma total antioxidant capacity without having a significant effect on oxLDL/β2GPI complexes. This might be explained by either different mechanism involved in oxLDL/β2GPI complexes formation compared with oxLDL formation, or by an interfering effect of HRT on the susceptibility of LDL to oxidation. In conclusion, we propose that beneficial effects of HRT could be explained, at least in part, by improving antioxidant status, but may not be directly associated with altering the oxidized lipoprotein production.

Acknowledgment

This study was supported by a grant from the Isfahan University of Medical Sciences.

Conflict of interest

The authors declare that they have no conflict of interest.
References


1776.